Loading...

OLMA OLEMA PHARMACEUTICALS INC Operational Disruptions 8-K Filing

LM P

LM

OLEMA PHARMACEUTICALS INC

(OLMA)

2024 8-K

Public Offering Announcement

ATM Prospectus Termination

Quarterly Results

Clinical Trial Agreement

Financial Statements

Financial Results

Investor Presentation

Investor Presentation

Equity Exchange

Collaboration Agreement

Financial Results

Corporate Presentation

Financial Results

Loan Agreement Amendment

Annual Meeting Voting Results

Clinical Study Results

Financial Results

Financial Results

Investor Presentation

Announcement of Development...

Equity Offering Program

Investor Presentation

Clinical Study Results

Financial Results

Phase 2 Clinical Study Results

Amendment and Appointment

Appointment of Director

Amendment to Clinical Colla...

Financial Results for Q2 2023

Annual Meeting Voting Results

Clinical Study Results

Financial Results

Regulation FD Disclosure

Financial Results

External Links:

Olema Pharmaceuticals announced interim results from a Phase 1b/2 clinical study of palazestrant in combination with ribociclib for the treatment of metastatic breast cancer.

AI Assistant

OLEMA PHARMACEUTICALS INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.